Yunnan Baiyao group reports strong H1 2025 earnings, sets new record

For the first half of 2025, Yunnan Baiyao Group reported operating revenue of yuan 21.257 bn, a 3.92% year-on-year increase. Net profit attributable to shareholders of the listed company reached yuan 3.633 bn, up 13.93% from the previous year, setting a new record for the period. Industrial revenue, a key growth driver, increased by 11.13% and now accounts for 40.01% of total operating revenue.

The Pharmaceutical Business Group's income grew by 10.8% to yuan 4.751 bn, with Yunnan Baiyao Aerosol sales exceeding yuan 1.453 bn, a 20.9% increase. The Health Products Business Group recorded operating income of yuan 3.442 bn, up 9.46%. The TCM Resources Business Group also saw growth, with operating income of yuan 914 m, a 6.3% increase. Yunnan Pharma's main business income reached yuan 12.164 bn, with a net profit of yuan 351 m, up 17.75% year-on-year.

The company's net operating cash flow surged by 21.45% to yuan 3.961 bn, and total assets grew by 3.06% to yuan 54.535 bn. A cash dividend of yuan 10.19 (tax inclusive) per 10 shares will be paid to all shareholders for the second quarter of 2025, totaling yuan 1,818,163,592.46.